Commercialization challenges associated with induced pluripotent stem cell-based products

ISSN： 1746-0751

Source： Regenerative Medicine, Vol.5, Iss.4, 2010-07, pp. : 593-603

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Promises and challenges of the first clinical-grade induced pluripotent stem cell bank

By Ilic Dusko Stephenson Emma

Regenerative Medicine, Vol. 8, Iss. 2, 2013-03 ,pp. : 101-102

Future Medicine

Access to resources Recommend Favorite

Induced pluripotent stem cells: opportunities and challenges

By Lensch M William Rao Mahendra

Regenerative Medicine, Vol. 5, Iss. 4, 2010-07 ,pp. : 483-484

Future Medicine

Access to resources Recommend Favorite

Induced pluripotent stem cell technology for generating photoreceptors

By Boucherie Céédric Sowden Jane C Ali Robin R

Regenerative Medicine, Vol. 6, Iss. 4, 2011-07 ,pp. : 469-479

Future Medicine

Access to resources Recommend Favorite

Patent Eligibility of Induced Pluripotent Stem Cell Theranostics

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 4, 2013-04 ,pp. : 318-320

John Wiley & Sons Inc

Access to resources Recommend Favorite

Valproic acid‐induced hepatotoxicity in alpers syndrome is associated with mitochondrial permeability transition pore opening‐dependent apoptotic sensitivity in an induced pluripotent stem cell model

HEPATOLOGY, Vol. 61, Iss. 5, 2015-05 ,pp. : 1730-1739

John Wiley & Sons Inc

Access to resources Recommend Favorite